Drug Trial Radar · NCT05077709
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
63
Actual
Start
Apr 11, 2022
Primary completion
Nov 30, 2025
Study completion Feb 8, 2026
Sponsor
- Lead sponsor
- IO BiotechIndustry
- Sponsor type
- Industry
- Collaborators
- Theradex; Almac; NeoGenomics; Merck Sharp & Dohme LLC
- First posted
- Oct 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
Conditions
- Lung Cancer Non Small Cell
- Head and Neck Squamous Cell Carcinoma
- Urothelial Carcinoma Bladder
Interventions
IO102-IO103 in combination with pembrolizumabDrug
The experimental drug IO102-IO103 is for SC injection and consist of IDO and PD-L1 peptides
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: From date of informed consent until disease progression, death or withdrawal of consent whichever came first, assessed for up to 3 years.
Locations
21 sites in 3 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
UC Davis Cancer Center
Sacramento, California
University of California San Diego
San Diego, California
Mid Florida Hematology and Oncology Center
Orange City, Florida
Montefiore Medical Center
The Bronx, New York
University of Toledo Medical Center
Toledo, Ohio
Oregon Health & Science University
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Virginia Cancer Specialists
Fairfax, Virginia
Hospital Vall d'Hebron
Barcelona, Spain
Institut Català d'Oncologia (ICO) Badalona (Catalan Institute of Oncology)
Barcelona, Spain
Hospital Universitari de Girona Doctor Josep Trueta
Girona, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Hospital Universitario Virgen Macarena
Seville, Sevilla, Spain
Hospital Clínico Universitario de Valencia
Valencia, Valencia, Spain
Hospital Clínico Lozano Blesa
Zaragoza, Zaragoza, Spain
Velindre Cancer Center
Cardiff, United Kingdom
Guys and St Thomas Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.